Brazilian researchers map cancer protein to unlock future treatments

NCT ID NCT07101081

Not yet recruiting Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study aims to understand how common a specific protein called HER2 is in five types of gynecological cancers. Researchers will analyze stored tumor tissue samples from 350 adult patients in Brazil to measure HER2 levels. The goal is to gather information that could help guide the development of future targeted treatments for these cancers.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GYNAECOLOGICAL CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Oncoclínicas Precision Medicine

    São Paulo, São Paulo, Brazil

Conditions

Explore the condition pages connected to this study.